Protara Therapeutics (TARA) investor relations material

Executive summary

• Clinical-stage biopharma focused on cancer and rare diseases, with lead programs TARA-002 (cell therapy for NMIBC and LMs) and IV Choline Chloride (for parenteral support patients).

• Advanced late-stage pipeline with progress in key clinical trials for cancer and rare diseases.

• No approved products or revenue; significant operating losses expected to continue as development progresses.

• As of June 30, 2026, $161.9M in unrestricted cash and marketable securities; accumulated deficit of $341.9M.

• Enrollment for the ADVANCED-2 BCG-Unresponsive cohort and STARBORN-1 LM trial expected to complete in Q4 2026.

Financial highlights

• Net loss of $21.7M for Q2 2026, up from $15.0M in Q2 2025; net loss of $39.5M for H1 2026, up from $26.9M in H1 2025.

• Operating expenses rose to $23.3M in Q2 2026 (from $16.6M in Q2 2025) and $43.0M in H1 2026 (from $30.7M in H1 2025).

• Research and development expenses increased by $6.2M year-over-year for Q2 and $10.6M for H1, driven by higher clinical trial and personnel costs.

• General and administrative expenses increased by $0.6M in Q2 and $1.6M in H1 year-over-year, mainly due to higher personnel costs.

• Interest and investment income was $1.7M in Q2 2026, up slightly from $1.6M in Q2 2025.

Outlook and guidance

• Cash runway expected to support planned operations and milestones into 2028.

• Enrollment for the BCG-Unresponsive cohort in the ADVANCED-2 trial and STARBORN-1 trial for LMs expected to complete in Q4 2026.

• Interim results from the THRIVE-3 trial for IV Choline Chloride anticipated in Q4 2026.

• BLA submission for TARA-002 in LMs anticipated in 2H 2027.

• Current financial resources expected to cover liquidity needs for at least 12 months from the reporting date.